Early data from Roche’s NHL drug mosunetuzumab steals the show at ASHThere’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising Share XEarly data from Roche’s NHL drug mosunetuzumab steals the show at ASHhttps://pharmaphorum.com/news/early-data-from-roches-mosunetuzumab-steals-the-show-at-ash/
FDA approves Roche’s MRSA test, allowing for faster screeningThe FDA has approved Roche’s MRSA test, a technology that could give healthcare providers the ability to detect Share XFDA approves Roche’s MRSA test, allowing for faster screeninghttps://pharmaphorum.com/news/fda-approves-roches-mrsa-test/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
Creating solutions, not products, in diabetesRoche Diabetes Care’s Michael Goetzl explains how the company is spearheading a combined digital-pharmaceutical approach to diabetes and Share XCreating solutions, not products, in diabeteshttps://deep-dive.pharmaphorum.com/magazine/digital-health/creating-solutions-not-products-in-diabetes-roche/
Mylan and Biocon launch Herceptin biosimilar in USMylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast Share XMylan and Biocon launch Herceptin biosimilar in UShttps://pharmaphorum.com/news/mylan-and-biocon-launch-herceptin-biosimilar-in-us/
Roche trumpets data for Soliris rival in NMOSD after US, EU filingsRoche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum Share XRoche trumpets data for Soliris rival in NMOSD after US, EU filingshttps://pharmaphorum.com/news/roche-trumpets-data-for-soliris-rival-in-nmosd-after-us-eu-filings/
Drugs firms make massive discounts to get reimbursement in ChinaRoche and Novartis are among the pharmaceuticals companies who have agreed to cut prices of some of their Share XDrugs firms make massive discounts to get reimbursement in Chinahttps://pharmaphorum.com/news/drugs-firms-make-massive-discounts-to-get-reimbursement-in-china/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
